Platform to Discuss Latest Worldwide Research
Rye, New York -- Approximately 350 medical doctors from around the world are scheduled to attend the 10th International Symposium of the AHCC(R) (Active Hexose Correlated Compound) and GCP(R) (Genistein Combined Polysaccharide) Research Associations meeting August 23-25, 2002, in Sapporo, Japan.
The Symposium is co-sponsored by The Foundation for Basic Research of Oncology (the association authorized by the Japanese Ministry of Health and Welfare as an official foundation to execute and support basic research projects on cancer) and Amino Up Chemical Co., Ltd., headquartered in Sapporo, Japan.
“This Symposium proves the worldwide commitment to establishing solid research behind AHCC and GCP -- it’s truly a one of a kind gathering,” stated Fred Pescatore, M.D., M.P.H., of the Centers For Integrative and Complementary Medicine, and medical director for the U.S. AHCC Research Association. “Each year the Symposium grows in size and context. As more doctors from around the world become aware of the benefits of AHCC and GCP, they are invited to share their research as well as converse with others in their field on future projects.”
The focus of the Symposium is to discuss new AHCC and GCP clinical research studies and developments. The agenda currently consists of four basic studies and ten clinical studies on AHCC, two basic studies and three clinical studies on GCP and one basic study and one clinical study on the combined usage of AHCC and GCP. The keynote lecturer, Dr. Noriaki Tanaka (Okayama Univ.) will be speaking on The Current Tumor Therapy. Present registered nations include China, Finland, Japan, Korea, New Zealand, Thailand, United Kingdom and the United States.
One significant AHCC study to be highlighted at the Symposium is titled "Improved Prognosis of Postoperative Hepatocellular Carcinoma Patients When Treated with Functional Foods: A Prospective Cohort Study” conducted by Dr. Yasuo Kamiyama, Professor of Kansai Medical University in Osaka, Japan. The study measures the effects of AHCC on post-operative liver cancer patients over a nine-year period based on ten different parameters. A synopsis of the study is scheduled for publication in the July edition of the Journal of Hepatology -- The Official Journal of the European Association for the Study of Liver.
The AHCC Research Association, www.AHCCresearch.com, and the GCP Research Association, www.GCPresearch.com, were established in the U.S. to promote clinical research of the nutritional supplements, as well as physician and patient education of its benefits.
AHCC is derived from a highly specialized manufacturing process developed in the mid-1980s that relies on the hybridization of several species of mushrooms cultivated in Japan. According to industry analysts in Japan, over 700 hospitals and medical clinics recommend AHCC to patients in that country as part of an immune enhancement maintenance regimen, creating a $150 million (USD) industry. The ingredient, AHCC, is the recent recipient of the esteemed NutrAward-- Nutracon Best New Product of 2002.
GCP is an extract produced through the fermentation of soybean isoflavones and medicinal mushrooms. Numerous research studies have shown that GCP inhibits angiogenesis and cell proliferation. GCP is well tolerated by the body with no known serious side effects and is highly bioavailable for use by the body.
Further details of the 10th International Symposium of AHCC(R) and GCP(R) Research Associations will be available as the event nears. The Symposium is also open to members of the media. If you are interested in attending or would like more press information, contact Tiia Sumera at [email protected] or visit www.AHCCresearch.com or www.GCPresearch.com.